GlaxoSmithKline Pharmaceuticals delivers strong financials led by Pharma growth

GlaxoSmithKline Pharmaceuticals Ltd today declared its financial results for the quarter ended December 31, 2021. Revenue for the quarter from Continuing Operations came in at Rs 808 crores recording a growth of 2%. PBT (before exceptional items) from Continuing Operations for the quarter at Rs 189 crores recorded a growth of 6%. EBITDA from Continuing Operations at Rs 197 crores recorded a growth of 8%.

Revenue from Continuing Operations for the nine months ended December 31, 2021 was Rs 2426 crores recording a growth of 11 %. PST (before exceptional items) from Continuing Operations for the nine months at Rs 585 crores recorded a growth of 27%. EBITDA from Continuing Operations at Rs 582 crores recorded a growth of 31 %.

Commenting on the results, Sridhar Venkatesh, Managing Director, GlaxoSmithKline Pharmaceuticals Limited, said, "GSK's established pharma portfolio recorded strong doubledigit growth, driven by our core legacy brands such as Ca/pol, Augmentin and Ceftum.

While our promoted brands grew, our vaccines business was impacted on account of the third wave of the pandemic. However, as this phase of the pandemic recedes and schools open up across the country, we are witnessing a steady uptake in vaccination. We also continue to invest in our brands and raise awareness amongst parents about more innovative vaccines from our portfolio.

During the quarter, we concluded the sale of the Vemgal plant in Karnataka. In the subsequent quarters, we will also aim to close the transfer of lodex and Ostocalcium brands to GlaxoSmithKline Asia Private Limited, as part of GSK pie's plans to create two world class companies in pharmaceuticals and consumer healthcare."

Shares of GlaxoSmithKline Pharmaceuticals Limited was last trading in BSE at Rs. 1580.45 as compared to the previous close of Rs. 1572.30. The total number of shares traded during the day was 1714 in over 472 trades.

The stock hit an intraday high of Rs. 1590.30 and intraday low of 1570.25. The net turnover during the day was Rs. 2707576.00.

Source : Equity Bulls

Keywords

GlaxoSmithKlinePharmaceuticals INE159A01016 Q3FY22 9MFY22 ResultUpdate